

TDMS No. 20011 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS

1-Bromopropane

CAS Number: 106-94-5

F1_M3

Date Report Requested: 10/01/2008

Time Report Requested: 09:42:38

First Dose M/F: 07/21/03 / 07/21/03

Lab: BNW

C Number: C20011
Lock Date: 06/15/2006
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.0.0

TDMS No. 20011 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS

1-Bromopropane

CAS Number: 106-94-5

Date Report Requested: 10/01/2008

Time Report Requested: 09:42:38

First Dose M/F: 07/21/03 / 07/21/03

Lab: BNW

HISTORICAL CONTROL STUDIES From October 2007 Report

SAME ROUTE

- 96011-06 -- Cumene (INHALATION AIR)
- 88004-06 -- Divinylbenzene (INHALATION AIR)
- 97006-02 -- Methyl isobutyl ketone (INHALATION AIR)
- 88006-04 -- alpha-Methylstyrene (INHALATION AIR)
- 97008-06 -- Propargyl alcohol (INHALATION AIR)
- 96001-06 -- Stoddard solvent (type IIC) (INHALATION AIR)

ALL ROUTES

- 88138-04 -- Benzophenone (ORAL FEED)
- 99027-04 -- Chromium picolinate monohydrate (ORAL FEED)
- 05174-06 -- Cresols (ORAL FEED)
- 96011-06 -- Cumene (INHALATION AIR)
- 97003-08 -- 1,2-Dibromo-2,4-dicyanobutane (SKIN ETHANOL)
- 93020-08 -- Diisopropylcarbodiimide (SKIN ETHANOL)
- 88004-06 -- Divinylbenzene (INHALATION AIR)
- 88123-07 -- Formamide (GAVAGE WATER)
- 95011-06 -- 5-(Hydroxymethyl)-2-furfural (GAVAGE WATER)
- 88105-04 -- Isoeugenol (GAVAGE CORN OIL)
- 97006-02 -- Methyl isobutyl ketone (INHALATION AIR)
- 91005-08 -- Methylene blue trihydrate (GAVAGE METHYLCELLULOSE)
- 92012-06 -- 2-Methylimidazole (ORAL FEED)
- 92013-06 -- 4-Methylimidazole (ORAL FEED)
- 88006-04 -- alpha-Methylstyrene (INHALATION AIR)
- 99023-04 -- beta-Myrcene (GAVAGE CORN OIL)
- 97008-06 -- Propargyl alcohol (INHALATION AIR)
- 20114-06 -- Sodium dichromate dihydrate (VI) (ORAL WATER)
- 96001-06 -- Stoddard solvent (type IIC) (INHALATION AIR)

TDMS No. 20011 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS

1-Bromopropane

CAS Number: 106-94-5

Date Report Requested: 10/01/2008

Time Report Requested: 09:42:38

First Dose M/F: 07/21/03 / 07/21/03

Lab: BNW

**HISTORICAL CONTROL STUDIES
From October 2007 Report**

05109-14 -- Triethanolamine (SKIN ACETONE)

96019-06 -- Water disinfection byproducts (Bromochloroacetic acid) (ORAL WATER)

96018-04 -- Water disinfection byproducts (Bromodichloromethane) (ORAL WATER)

96017-06 -- Water disinfection byproducts (Dibromoacetic acid) (ORAL WATER)

96015-06 -- Water disinfection byproducts (Dibromoacetonitrile) (ORAL WATER)

96010-04 -- Water disinfection byproducts (Sodium chlorate) (ORAL WATER)

TDMS No. 20011 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS

1-Bromopropane

CAS Number: 106-94-5

Date Report Requested: 10/01/2008

Time Report Requested: 09:42:38

First Dose M/F: 07/21/03 / 07/21/03

Lab: BNW

**FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS RATES ARE BASED ON THE NUMBER OF ANIMALS NECROPSIED.**

Adrenal Cortex
Adrenal Medulla
Bone Marrow
Brain
Clitoral/Preputial Gland
Heart
Islets, Pancreatic
Liver
Lung
Ovary
Pancreas
Pituitary Gland
Spleen
Testes
Thymus
Urinary Bladder

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF 1-Bromopropane

MALE MICE

Organ

Adrenal Cortex
Harderian Gland

Intestine Small: Jejunum
Intestine Small: Site Unspecified
Liver

Stomach, Forestomach
All Organs

FEMALE MICE

Organ

Adrenal Medulla

Liver

Lung

Pituitary Gland: Pars Intermedia
Skin

Stomach, Forestomach
Uterus
All Organs

Morphology

Adenoma
Adenoma
Carcinoma or Adenoma
Carcinoma
Carcinoma
Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Squamous Cell Papilloma
Malignant and Benign Tumors

Morphology

Pheochromocytoma Benign
Pheochromocytoma: Benign, Complex, Malignant, NOS
Hepatocellular Carcinoma
Hepatocellular Carcinoma or Hepatoblastoma
Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Alveolar/Bronchiolar Adenoma
Alveolar/Bronchiolar Carcinoma
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma
Adenoma
Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma
Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma
Sarcoma
Squamous Cell Papilloma
Polyp Stromal
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type
Benign Tumors

TDMS No. 20011 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS

1-Bromopropane

CAS Number: 106-94-5

Date Report Requested: 10/01/2008

Time Report Requested: 09:42:38

First Dose M/F: 07/21/03 / 07/21/03

Lab: BNW

SUMMARY OF STATISTICALLY SIGNIFICANT ($P \leq .05$) RESULTS IN THE ANALYSIS OF 1-Bromopropane

Malignant Tumors

Malignant and Benign Tumors

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Adrenal Cortex
Adenoma**

TUMOR RATES

OVERALL (a)	4/49 (8%)	3/50 (6%)	2/49 (4%)	0/50 (0%)
POLY-3 RATE (b)	4/43.79	3/43.61	2/44.54	0/41.84
POLY-3 PERCENT (g)	9.1%	6.9%	4.5%	0%
TERMINAL (d)	3/37 (8%)	2/33 (6%)	2/32 (6%)	0/36 (0%)
FIRST INCIDENCE	586	655	729 (T)	---
HC TUMORS SAME RTE	11/297 (4%)			
HC TUMORS ALL RTES	74/1142 (7%)			

STATISTICAL TESTS

POLY 3	P=0.040N*	P=0.502N	P=0.329N	P=0.066N
POLY 1.5	P=0.040N*	P=0.495N	P=0.328N	P=0.065N
POLY 6	P=0.040N*	P=0.515N	P=0.340N	P=0.067N
COCH-ARM / FISHERS	P=0.036N*	P=0.489N	P=0.339N	P=0.056N
MAX-ISO-POLY-3	P=0.050N*	P=0.350N	P=0.196N	P=0.024N*
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Adrenal Medulla
Pheochromocytoma Benign**

TUMOR RATES

OVERALL (a)	1/50 (2%)	0/49 (0%)	1/49 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/44.31	0/43.1	1/44.54	0/41.84
POLY-3 PERCENT (g)	2.3%	0%	2.3%	0%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	1/32 (3%)	0/36 (0%)
FIRST INCIDENCE	691	---	729 (T)	---
HC TUMORS SAME RTE	2/294 (1%)			
HC TUMORS ALL RTES	4/1135 (0%)			

STATISTICAL TESTS

POLY 3	P=0.412N	P=0.506N	P=0.760N	P=0.511N
POLY 1.5	P=0.412N	P=0.504N	P=0.760N	P=0.510N
POLY 6	P=0.410N	P=0.509N	P=0.758	P=0.512N
COCH-ARM / FISHERS	P=0.405N	P=0.505N	P=0.747	P=0.500N
MAX-ISO-POLY-3	P=0.280N	P=0.164N	P=0.498N	P=0.173N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Adrenal Medulla
Pheochromocytoma: Benign, Complex, Malignant, NOS**

TUMOR RATES

OVERALL (a)	1/50 (2%)	0/49 (0%)	1/49 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/44.31	0/43.1	1/44.54	1/41.84
POLY-3 PERCENT (g)	2.3%	0%	2.3%	2.4%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	1/32 (3%)	1/36 (3%)
FIRST INCIDENCE	691	---	729 (T)	729 (T)
HC TUMORS SAME RTE	3/294 (1%)			
HC TUMORS ALL RTES	8/1135 (1%)			

STATISTICAL TESTS

POLY 3	P=0.523	P=0.506N	P=0.760N	P=0.748
POLY 1.5	P=0.523	P=0.504N	P=0.760N	P=0.749
POLY 6	P=0.525	P=0.509N	P=0.758	P=0.748
COCH-ARM / FISHERS	P=0.540	P=0.505N	P=0.747	P=0.753N
MAX-ISO-POLY-3	P=0.532	P=0.164N	P=0.498N	P=0.483
HISTCONT SAME RTE	P=0.528	(e)	P=0.408	P=0.396
HISTCONT ALL RTES	P=0.286	(e)	P=0.254	P=0.248

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM
Harderian Gland Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	7/50 (14%)	3/50 (6%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	7/44.16	3/43.64	2/45.4	3/41.84
POLY-3 PERCENT (g)	15.9%	6.9%	4.4%	7.2%
TERMINAL (d)	7/37 (19%)	1/33 (3%)	1/32 (3%)	3/36 (8%)
FIRST INCIDENCE	729 (T)	684	702	729 (T)
HC TUMORS SAME RTE	38/300 (13%)			
HC TUMORS ALL RTES	152/1149 (13%)			

STATISTICAL TESTS

POLY 3	P=0.133N	P=0.161N	P=0.072N	P=0.179N
POLY 1.5	P=0.134N	P=0.159N	P=0.073N	P=0.178N
POLY 6	P=0.131N	P=0.165N	P=0.074N	P=0.177N
COCH-ARM / FISHERS	P=0.128N	P=0.159N	P=0.080N	P=0.159N
MAX-ISO-POLY-3	P=0.082N	P=0.093N	P=0.036N*	P=0.110N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM
Harderian Gland Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	3/50 (6%)	1/50 (2%)	7/50 (14%)	5/50 (10%)
POLY-3 RATE (b)	3/44.16	1/43.34	7/46.42	5/41.84
POLY-3 PERCENT (g)	6.8%	2.3%	15.1%	12%
TERMINAL (d)	3/37 (8%)	1/33 (3%)	3/32 (9%)	5/36 (14%)
FIRST INCIDENCE	729 (T)	729 (T)	604	729 (T)
HC TUMORS SAME RTE	11/300 (4%)			
HC TUMORS ALL RTES	30/1149 (3%)			

STATISTICAL TESTS

POLY 3	P=0.123	P=0.312N	P=0.178	P=0.327
POLY 1.5	P=0.123	P=0.308N	P=0.173	P=0.329
POLY 6	P=0.127	P=0.319N	P=0.177	P=0.327
COCH-ARM / FISHERS	P=0.145	P=0.309N	P=0.159	P=0.357
MAX-ISO-POLY-3	P=0.125	P=0.161N	P=0.109	P=0.213
HISTCONT SAME RTE	P=0.043*	P=1.000	P=0.050*	P=0.104
HISTCONT ALL RTES	P=0.002**	P=1.000	P=0.009**	P=0.040*

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM
Harderian Gland Carcinoma or Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	10/50 (20%)	4/50 (8%)	8/50 (16%)	8/50 (16%)
POLY-3 RATE (b)	10/44.16	4/43.64	8/46.53	8/41.84
POLY-3 PERCENT (g)	22.7%	9.2%	17.2%	19.1%
TERMINAL (d)	10/37 (27%)	2/33 (6%)	3/32 (9%)	8/36 (22%)
FIRST INCIDENCE	729 (T)	684	604	729 (T)
HC TUMORS SAME RTE	48/300 (16%)			
HC TUMORS ALL RTES	176/1149 (15%)			

STATISTICAL TESTS

POLY 3	P=0.547	P=0.074N	P=0.350N	P=0.446N
POLY 1.5	P=0.545	P=0.073N	P=0.363N	P=0.443N
POLY 6	P=0.550N	P=0.076N	P=0.346N	P=0.444N
COCH-ARM / FISHERS	P=0.527N	P=0.074N	P=0.398N	P=0.398N
MAX-ISO-POLY-3	P=0.300N	P=0.041N*	P=0.264N	P=0.347N
HISTCONT SAME RTE	P=0.669	P=1.000	P=1.000	P=0.525
HISTCONT ALL RTES	P=0.655	P=1.000	P=0.594	P=0.488

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM
Intestine Small: Jejunum Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	4/50 (8%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	4/44.16	1/43.69	1/45.48	0/41.84
POLY-3 PERCENT (g)	9.1%	2.3%	2.2%	0%
TERMINAL (d)	4/37 (11%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	631	682	---
HC TUMORS SAME RTE	5/300 (2%)			
HC TUMORS ALL RTES	14/1149 (1%)			

STATISTICAL TESTS

POLY 3	P=0.034N*	P=0.181N	P=0.170N	P=0.067N
POLY 1.5	P=0.035N*	P=0.180N	P=0.171N	P=0.067N
POLY 6	P=0.034N*	P=0.185N	P=0.173N	P=0.067N
COCH-ARM / FISHERS	P=0.034N*	P=0.181N	P=0.181N	P=0.059N
MAX-ISO-POLY-3	P=0.019N*	P=0.086N	P=0.081N	P=0.025N*
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Intestine Small: Site Unspecified
Carcinoma**

TUMOR RATES

	#	#	#	#
OVERALL (a)	4/50 (8%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	4/44.16	1/43.69	1/45.48	0/41.84
POLY-3 PERCENT (g)	9.1%	2.3%	2.2%	0%
TERMINAL (d)	4/37 (11%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	631	682	---
HC TUMORS SAME RTE	5/300 (2%)			
HC TUMORS ALL RTES	18/1149 (2%)			

STATISTICAL TESTS

POLY 3	P=0.034N*	P=0.181N	P=0.170N	P=0.067N
POLY 1.5	P=0.035N*	P=0.180N	P=0.171N	P=0.067N
POLY 6	P=0.034N*	P=0.185N	P=0.173N	P=0.067N
COCH-ARM / FISHERS	P=0.034N*	P=0.181N	P=0.181N	P=0.059N
MAX-ISO-POLY-3	P=0.019N*	P=0.086N	P=0.081N	P=0.025N*
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Hepatocellular Adenoma**

TUMOR RATES

OVERALL (a)	30/50 (60%)	32/50 (64%)	33/50 (66%)	23/50 (46%)
POLY-3 RATE (b)	30/48.02	32/47.36	33/48.32	23/43.13
POLY-3 PERCENT (g)	62.5%	67.6%	68.3%	53.3%
TERMINAL (d)	23/37 (62%)	24/33 (73%)	21/32 (66%)	20/36 (56%)
FIRST INCIDENCE	328	424	537	417
HC TUMORS SAME RTE	141/299 (47%)			
HC TUMORS ALL RTES	544/1146 (48%)			

STATISTICAL TESTS

POLY 3	P=0.186N	P=0.377	P=0.347	P=0.248N
POLY 1.5	P=0.159N	P=0.396	P=0.346	P=0.217N
POLY 6	P=0.197N	P=0.349	P=0.343	P=0.267N
COCH-ARM / FISHERS	P=0.066N	P=0.418	P=0.339	P=0.115N
MAX-ISO-POLY-3	P=0.180N	P=0.299	P=0.272	P=0.198N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Hepatocellular Carcinoma**

TUMOR RATES

OVERALL (a)	15/50 (30%)	15/50 (30%)	19/50 (38%)	11/50 (22%)
POLY-3 RATE (b)	15/45.89	15/45.28	19/48.58	11/43.26
POLY-3 PERCENT (g)	32.7%	33.1%	39.1%	25.4%
TERMINAL (d)	9/37 (24%)	8/33 (24%)	8/32 (25%)	7/36 (19%)
FIRST INCIDENCE	539	520	537	470
HC TUMORS SAME RTE	74/299 (25%)			
HC TUMORS ALL RTES	317/1146 (28%)			

STATISTICAL TESTS

POLY 3	P=0.289N	P=0.571	P=0.332	P=0.302N
POLY 1.5	P=0.288N	P=0.581	P=0.311	P=0.296N
POLY 6	P=0.287N	P=0.552	P=0.340	P=0.305N
COCH-ARM / FISHERS	P=0.233N	P=0.586N	P=0.263	P=0.247N
MAX-ISO-POLY-3	P=0.284N	P=0.481	P=0.264	P=0.233N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Hepatocellular Carcinoma or Hepatoblastoma**

TUMOR RATES

OVERALL (a)	16/50 (32%)	16/50 (32%)	19/50 (38%)	11/50 (22%)
POLY-3 RATE (b)	16/45.89	16/45.28	19/48.58	11/43.26
POLY-3 PERCENT (g)	34.9%	35.3%	39.1%	25.4%
TERMINAL (d)	10/37 (27%)	9/33 (27%)	8/32 (25%)	7/36 (19%)
FIRST INCIDENCE	539	520	537	470
HC TUMORS SAME RTE	75/299 (25%)			
HC TUMORS ALL RTES	346/1146 (30%)			

STATISTICAL TESTS

POLY 3	P=0.208N	P=0.569	P=0.415	P=0.230N
POLY 1.5	P=0.208N	P=0.579	P=0.393	P=0.225N
POLY 6	P=0.205N	P=0.549	P=0.425	P=0.233N
COCH-ARM / FISHERS	P=0.163N	P=0.585N	P=0.338	P=0.184N
MAX-ISO-POLY-3	P=0.232N	P=0.480	P=0.339	P=0.173N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Hepatocellular Carcinoma or Hepatocellular Adenoma**

TUMOR RATES

OVERALL (a)	38/50 (76%)	38/50 (76%)	41/50 (82%)	28/50 (56%)
POLY-3 RATE (b)	38/48.94	38/48.67	41/49.8	28/44.38
POLY-3 PERCENT (g)	77.7%	78.1%	82.3%	63.1%
TERMINAL (d)	28/37 (76%)	25/33 (76%)	24/32 (75%)	22/36 (61%)
FIRST INCIDENCE	328	424	537	417
HC TUMORS SAME RTE	185/299 (62%)			
HC TUMORS ALL RTES	729/1146 (64%)			

STATISTICAL TESTS

POLY 3	P=0.066N	P=0.578	P=0.370	P=0.089N
POLY 1.5	P=0.053N	P=0.585	P=0.345	P=0.073N
POLY 6	P=0.072N	P=0.564	P=0.405	P=0.099N
COCH-ARM / FISHERS	P=0.013N*	P=0.592N	P=0.312	P=0.028N*
MAX-ISO-POLY-3	P=0.060N	P=0.479	P=0.281	P=0.066N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma**

TUMOR RATES

OVERALL (a)	38/50 (76%)	39/50 (78%)	41/50 (82%)	28/50 (56%)
POLY-3 RATE (b)	38/48.94	39/48.67	41/49.8	28/44.38
POLY-3 PERCENT (g)	77.7%	80.1%	82.3%	63.1%
TERMINAL (d)	28/37 (76%)	26/33 (79%)	24/32 (75%)	22/36 (61%)
FIRST INCIDENCE	328	424	537	417
HC TUMORS SAME RTE	186/299 (62%)			
HC TUMORS ALL RTES	740/1146 (65%)			

STATISTICAL TESTS

POLY 3	P=0.055N	P=0.479	P=0.370	P=0.089N
POLY 1.5	P=0.043N*	P=0.489	P=0.345	P=0.073N
POLY 6	P=0.060N	P=0.461	P=0.405	P=0.099N
COCH-ARM / FISHERS	P=0.010N**	P=0.500	P=0.312	P=0.028N*
MAX-ISO-POLY-3	P=0.049N*	P=0.379	P=0.281	P=0.066N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Hepatocolangiocarcinoma**

TUMOR RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/44.57	1/43.87	1/45.3	2/42.38
POLY-3 PERCENT (g)	2.2%	2.3%	2.2%	4.7%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	1/32 (3%)	1/36 (3%)
FIRST INCIDENCE	610	568	729 (T)	562
HC TUMORS SAME RTE	6/299 (2%)			
HC TUMORS ALL RTES	9/1146 (1%)			

STATISTICAL TESTS

POLY 3	P=0.338	P=0.757	P=0.757N	P=0.482
POLY 1.5	P=0.338	P=0.759	P=0.756N	P=0.483
POLY 6	P=0.339	P=0.753	P=0.759	P=0.483
COCH-ARM / FISHERS	P=0.351	P=0.753N	P=0.753N	P=0.500
MAX-ISO-POLY-3	P=0.406	P=0.495	P=0.495N	P=0.271
HISTCONT SAME RTE	P=0.491	P=0.632	P=0.638	P=0.349
HISTCONT ALL RTES	P=0.129	P=0.421	P=0.426	P=0.168

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung
Alveolar/Bronchiolar Adenoma**

TUMOR RATES

OVERALL (a)	6/50 (12%)	5/50 (10%)	4/49 (8%)	5/49 (10%)
POLY-3 RATE (b)	6/45.25	5/43.34	4/44.5	5/41.89
POLY-3 PERCENT (g)	13.3%	11.5%	9%	11.9%
TERMINAL (d)	4/37 (11%)	5/33 (15%)	4/32 (13%)	4/36 (11%)
FIRST INCIDENCE	544	729 (T)	729 (T)	360
HC TUMORS SAME RTE	58/299 (19%)			
HC TUMORS ALL RTES	209/1148 (18%)			

STATISTICAL TESTS

POLY 3	P=0.476N	P=0.530N	P=0.380N	P=0.554N
POLY 1.5	P=0.475N	P=0.515N	P=0.376N	P=0.549N
POLY 6	P=0.475N	P=0.553N	P=0.397N	P=0.557N
COCH-ARM / FISHERS	P=0.453N	P=0.500N	P=0.383N	P=0.514N
MAX-ISO-POLY-3	P=0.545N	P=0.403N	P=0.262N	P=0.427N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung
Alveolar/Bronchiolar Carcinoma**

TUMOR RATES

OVERALL (a)	8/50 (16%)	7/50 (14%)	10/49 (20%)	10/49 (20%)
POLY-3 RATE (b)	8/44.9	7/43.98	10/45.41	10/41.1
POLY-3 PERCENT (g)	17.8%	15.9%	22%	24.3%
TERMINAL (d)	6/37 (16%)	6/33 (18%)	5/32 (16%)	9/36 (25%)
FIRST INCIDENCE	539	520	617	708
HC TUMORS SAME RTE	38/299 (13%)			
HC TUMORS ALL RTES	115/1148 (10%)			

STATISTICAL TESTS

POLY 3	P=0.209	P=0.518N	P=0.407	P=0.317
POLY 1.5	P=0.213	P=0.507N	P=0.402	P=0.326
POLY 6	P=0.210	P=0.537N	P=0.398	P=0.314
COCH-ARM / FISHERS	P=0.256	P=0.500N	P=0.379	P=0.379
MAX-ISO-POLY-3	P=0.333	P=0.405N	P=0.311	P=0.239
HISTCONT SAME RTE	P=0.021*	P=0.436	P=0.103	P=0.087
HISTCONT ALL RTES	P=0.009**	P=0.335	P=0.102	P=0.084

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma**

TUMOR RATES

OVERALL (a)	13/50 (26%)	12/50 (24%)	14/49 (29%)	15/49 (31%)
POLY-3 RATE (b)	13/45.99	12/43.98	14/45.41	15/41.98
POLY-3 PERCENT (g)	28.3%	27.3%	30.8%	35.7%
TERMINAL (d)	9/37 (24%)	11/33 (33%)	9/32 (28%)	13/36 (36%)
FIRST INCIDENCE	539	520	617	360
HC TUMORS SAME RTE	92/299 (31%)			
HC TUMORS ALL RTES	309/1148 (27%)			

STATISTICAL TESTS

POLY 3	P=0.225	P=0.552N	P=0.484	P=0.301
POLY 1.5	P=0.234	P=0.526N	P=0.490	P=0.317
POLY 6	P=0.219	P=0.593N	P=0.458	P=0.287
COCH-ARM / FISHERS	P=0.288	P=0.500N	P=0.475	P=0.387
MAX-ISO-POLY-3	P=0.355	P=0.459N	P=0.392	P=0.235
HISTCONT SAME RTE	P=0.427	P=1.000	P=0.511	P=0.302
HISTCONT ALL RTES	P=0.363	P=1.000	P=0.501	P=0.289

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Mammary Gland
 Adenosquamous Carcinoma**

TUMOR RATES

	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.16	0/43.34	0/45.3	0/41.84
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	0/1149 (0%)			

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Mammary Gland
Carcinoma**

TUMOR RATES

	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.16	0/43.34	0/45.3	0/41.84
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	1/1149 (0%)			

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Pituitary Gland: Pars Distalis or Unspecified Site
Adenoma**

TUMOR RATES

OVERALL (a)	1/46 (2%)	1/48 (2%)	0/46 (0%)	0/48 (0%)
POLY-3 RATE (b)	1/40.74	1/41.51	0/42.28	0/41.72
POLY-3 PERCENT (g)	2.5%	2.4%	0%	0%
TERMINAL (d)	1/36 (3%)	1/32 (3%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	---
HC TUMORS SAME RTE	1/290 (0%)			
HC TUMORS ALL RTES	3/1119 (0%)			

STATISTICAL TESTS

POLY 3	P=0.231N	P=0.757N	P=0.493N	P=0.495N
POLY 1.5	P=0.231N	P=0.753N	P=0.494N	P=0.495N
POLY 6	P=0.231N	P=0.759	P=0.495N	P=0.496N
COCH-ARM / FISHERS	P=0.231N	P=0.742N	P=0.500N	P=0.489N
MAX-ISO-POLY-3	P=0.251N	P=0.494N	P=0.158N	P=0.156N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Pituitary Gland: Pars Distalis or Unspecified Site
Carcinoma or Adenoma**

TUMOR RATES

OVERALL (a)	1/46 (2%)	1/48 (2%)	0/46 (0%)	0/48 (0%)
POLY-3 RATE (b)	1/40.74	1/41.51	0/42.28	0/41.72
POLY-3 PERCENT (g)	2.5%	2.4%	0%	0%
TERMINAL (d)	1/36 (3%)	1/32 (3%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	---
HC TUMORS SAME RTE	1/290 (0%)			
HC TUMORS ALL RTES	4/1119 (0%)			

STATISTICAL TESTS

POLY 3	P=0.231N	P=0.757N	P=0.493N	P=0.495N
POLY 1.5	P=0.231N	P=0.753N	P=0.494N	P=0.495N
POLY 6	P=0.231N	P=0.759	P=0.495N	P=0.496N
COCH-ARM / FISHERS	P=0.231N	P=0.742N	P=0.500N	P=0.489N
MAX-ISO-POLY-3	P=0.251N	P=0.494N	P=0.158N	P=0.156N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Pituitary Gland: Pars Intermedia
Adenoma**

TUMOR RATES

OVERALL (a)	0/46 (0%)	0/48 (0%)	0/46 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/40.74	0/41.51	0/42.28	0/41.72
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/32 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	1/290 (0%)			
HC TUMORS ALL RTES	3/1119 (0%)			

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Skin
Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/44.16	0/43.34	1/45.57	1/41.84
POLY-3 PERCENT (g)	0%	0%	2.2%	2.4%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	1/36 (3%)
FIRST INCIDENCE	---	---	655	729 (T)
HC TUMORS SAME RTE	7/300 (2%)			
HC TUMORS ALL RTES	14/1149 (1%)			

STATISTICAL TESTS

POLY 3	P=0.222	(e)	P=0.506	P=0.489
POLY 1.5	P=0.222	(e)	P=0.505	P=0.490
POLY 6	P=0.224	(e)	P=0.504	P=0.490
COCH-ARM / FISHERS	P=0.236	(e)	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.255	(e)	P=0.166	P=0.158
HISTCONT SAME RTE	P=0.307	(e)	P=0.209	P=0.198
HISTCONT ALL RTES	P=0.296	(e)	P=0.199	P=0.189

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Skin
Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/44.16	0/43.34	1/45.57	1/41.84
POLY-3 PERCENT (g)	0%	0%	2.2%	2.4%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	1/36 (3%)
FIRST INCIDENCE	---	---	655	729 (T)
HC TUMORS SAME RTE	7/300 (2%)			
HC TUMORS ALL RTES	11/1149 (1%)			

STATISTICAL TESTS

POLY 3	P=0.222	(e)	P=0.506	P=0.489
POLY 1.5	P=0.222	(e)	P=0.505	P=0.490
POLY 6	P=0.224	(e)	P=0.504	P=0.490
COCH-ARM / FISHERS	P=0.236	(e)	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.255	(e)	P=0.166	P=0.158
HISTCONT SAME RTE	P=0.307	(e)	P=0.209	P=0.198
HISTCONT ALL RTES	P=0.296	(e)	P=0.199	P=0.189

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Skin
Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/44.16	0/43.34	0/45.3	1/41.84
POLY-3 PERCENT (g)	0%	0%	0%	2.4%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	1/36 (3%)
FIRST INCIDENCE	---	---	---	729 (T)
HC TUMORS SAME RTE	4/300 (1%)			
HC TUMORS ALL RTES	5/1149 (0%)			

STATISTICAL TESTS

POLY 3	P=0.193	(e)	(e)	P=0.489
POLY 1.5	P=0.193	(e)	(e)	P=0.490
POLY 6	P=0.194	(e)	(e)	P=0.490
COCH-ARM / FISHERS	P=0.198	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.123	(e)	(e)	P=0.158
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM
Skin				
Sarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/44.16	0/43.34	1/45.57	0/41.84
POLY-3 PERCENT (g)	0%	0%	2.2%	0%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	655	---
HC TUMORS SAME RTE	3/300 (1%)			
HC TUMORS ALL RTES	6/1149 (1%)			

STATISTICAL TESTS

POLY 3	P=0.669	(e)	P=0.506	(e)
POLY 1.5	P=0.670	(e)	P=0.505	(e)
POLY 6	P=0.673	(e)	P=0.504	(e)
COCH-ARM / FISHERS	P=0.694	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.402	(e)	P=0.166	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Spleen
Hemangiosarcoma**

TUMOR RATES

OVERALL (a)	2/48 (4%)	1/50 (2%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/42.9	1/43.34	0/44.45	0/41.84
POLY-3 PERCENT (g)	4.7%	2.3%	0%	0%
TERMINAL (d)	2/37 (5%)	1/33 (3%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	---
HC TUMORS SAME RTE	4/297 (1%)			
HC TUMORS ALL RTES	21/1136 (2%)			

STATISTICAL TESTS

POLY 3	P=0.097N	P=0.496N	P=0.229N	P=0.243N
POLY 1.5	P=0.097N	P=0.491N	P=0.229N	P=0.241N
POLY 6	P=0.096N	P=0.506N	P=0.234N	P=0.244N
COCH-ARM / FISHERS	P=0.097N	P=0.485N	P=0.242N	P=0.237N
MAX-ISO-POLY-3	P=0.086N	P=0.278N	P=0.075N	P=0.083N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Stomach, Forestomach
Squamous Cell Papilloma**

TUMOR RATES

	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/44.16	0/43.34	0/45.3	2/41.84
POLY-3 PERCENT (g)	0%	0%	0%	4.8%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	2/36 (6%)
FIRST INCIDENCE	---	---	---	729 (T)
HC TUMORS SAME RTE	2/300 (1%)			
HC TUMORS ALL RTES	11/1149 (1%)			

STATISTICAL TESTS

POLY 3	P=0.044*	(e)	(e)	P=0.225
POLY 1.5	P=0.044*	(e)	(e)	P=0.226
POLY 6	P=0.044*	(e)	(e)	P=0.225
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.032*	(e)	(e)	P=0.076
HISTCONT SAME RTE	P=0.038*	(e)	(e)	P=0.072
HISTCONT ALL RTES	P=0.036*	(e)	(e)	P=0.083

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM
All Organs				
Hemangiosarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	4/50 (8%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	2/44.16	4/43.59	2/45.34	2/41.92
POLY-3 PERCENT (g)	4.5%	9.2%	4.4%	4.8%
TERMINAL (d)	2/37 (5%)	3/33 (9%)	1/32 (3%)	1/36 (3%)
FIRST INCIDENCE	729 (T)	661	718	708
HC TUMORS SAME RTE	16/300 (5%)			
HC TUMORS ALL RTES	67/1149 (6%)			

STATISTICAL TESTS

POLY 3	P=0.477N	P=0.331	P=0.684N	P=0.675
POLY 1.5	P=0.476N	P=0.335	P=0.685N	P=0.676
POLY 6	P=0.476N	P=0.324	P=0.691N	P=0.677
COCH-ARM / FISHERS	P=0.456N	P=0.339	P=0.691N	P=0.691N
MAX-ISO-POLY-3	P=0.528N	P=0.197	P=0.489N	P=0.478
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**All Organs
Hemangiosarcoma or Hemangioma**

TUMOR RATES

	#	#	#	#
OVERALL (a)	2/50 (4%)	4/50 (8%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	2/44.16	4/43.59	2/45.34	2/41.92
POLY-3 PERCENT (g)	4.5%	9.2%	4.4%	4.8%
TERMINAL (d)	2/37 (5%)	3/33 (9%)	1/32 (3%)	1/36 (3%)
FIRST INCIDENCE	729 (T)	661	718	708
HC TUMORS SAME RTE	19/300 (6%)			
HC TUMORS ALL RTES	76/1149 (7%)			

STATISTICAL TESTS

POLY 3	P=0.477N	P=0.331	P=0.684N	P=0.675
POLY 1.5	P=0.476N	P=0.335	P=0.685N	P=0.676
POLY 6	P=0.476N	P=0.324	P=0.691N	P=0.677
COCH-ARM / FISHERS	P=0.456N	P=0.339	P=0.691N	P=0.691N
MAX-ISO-POLY-3	P=0.528N	P=0.197	P=0.489N	P=0.478
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM
All Organs				
Histiocytic Sarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/44.16	2/44.01	1/45.3	0/41.84
POLY-3 PERCENT (g)	0%	4.5%	2.2%	0%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	1/32 (3%)	0/36 (0%)
FIRST INCIDENCE	---	540	729 (T)	---
HC TUMORS SAME RTE	3/300 (1%)			
HC TUMORS ALL RTES	7/1149 (1%)			

STATISTICAL TESTS

POLY 3	P=0.477N	P=0.236	P=0.505	(e)
POLY 1.5	P=0.476N	P=0.237	P=0.505	(e)
POLY 6	P=0.478N	P=0.234	P=0.502	(e)
COCH-ARM / FISHERS	P=0.461N	P=0.247	P=0.500	(e)
MAX-ISO-POLY-3	P=0.348	P=0.076	P=0.165	(e)
HISTCONT SAME RTE	(h)	(h)	(h)	(e)
HISTCONT ALL RTES	(h)	(h)	(h)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

All Organs
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type

TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	0/50 (0%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	2/44.66	0/43.34	3/45.3	0/41.84
POLY-3 PERCENT (g)	4.5%	0%	6.6%	0%
TERMINAL (d)	1/37 (3%)	0/33 (0%)	3/32 (9%)	0/36 (0%)
FIRST INCIDENCE	578	---	729 (T)	---
HC TUMORS SAME RTE	8/300 (3%)			
HC TUMORS ALL RTES	34/1149 (3%)			

STATISTICAL TESTS

POLY 3	P=0.313N	P=0.244N	P=0.506	P=0.252N
POLY 1.5	P=0.313N	P=0.240N	P=0.508	P=0.250N
POLY 6	P=0.310N	P=0.250N	P=0.495	P=0.253N
COCH-ARM / FISHERS	P=0.296N	P=0.247N	P=0.500	P=0.247N
MAX-ISO-POLY-3	P=0.181N	P=0.082N	P=0.330	P=0.090N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM
All Organs				
Benign Tumors				
TUMOR RATES	#	#	#	#
OVERALL (a)	36/50 (72%)	35/50 (70%)	35/50 (70%)	29/50 (58%)
POLY-3 RATE (b)	36/49.15	35/47.64	35/48.32	29/44.01
POLY-3 PERCENT (g)	73.2%	73.5%	72.4%	65.9%
TERMINAL (d)	26/37 (70%)	26/33 (79%)	23/32 (72%)	25/36 (69%)
FIRST INCIDENCE	328	424	537	360
HC TUMORS SAME RTE	200/300 (67%)			
HC TUMORS ALL RTES	753/1149 (66%)			

STATISTICAL TESTS

POLY 3	P=0.232N	P=0.582	P=0.556N	P=0.290N
POLY 1.5	P=0.188N	P=0.558N	P=0.529N	P=0.234N
POLY 6	P=0.275N	P=0.523	P=0.586	P=0.346N
COCH-ARM / FISHERS	P=0.073N	P=0.500N	P=0.500N	P=0.104N
MAX-ISO-POLY-3	P=0.360N	P=0.489	P=0.463N	P=0.229N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM
All Organs				
Malignant Tumors				
TUMOR RATES	#	#	#	#
OVERALL (a)	30/50 (60%)	30/50 (60%)	34/50 (68%)	24/50 (48%)
POLY-3 RATE (b)	30/47.86	30/47.28	34/49.29	24/43.8
POLY-3 PERCENT (g)	62.7%	63.5%	69%	54.8%
TERMINAL (d)	20/37 (54%)	18/33 (55%)	19/32 (59%)	19/36 (53%)
FIRST INCIDENCE	328	520	537	470
HC TUMORS SAME RTE	146/300 (49%)			
HC TUMORS ALL RTES	582/1149 (51%)			

STATISTICAL TESTS

POLY 3	P=0.270N	P=0.554	P=0.329	P=0.289N
POLY 1.5	P=0.243N	P=0.563	P=0.311	P=0.260N
POLY 6	P=0.296N	P=0.543	P=0.332	P=0.316N
COCH-ARM / FISHERS	P=0.132N	P=0.581N	P=0.266	P=0.158N
MAX-ISO-POLY-3	P=0.268N	P=0.468	P=0.259	P=0.230N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**All Organs
Malignant and Benign Tumors**

TUMOR RATES

	#	#	#	#
OVERALL (a)	47/50 (94%)	47/50 (94%)	46/50 (92%)	36/50 (72%)
POLY-3 RATE (b)	47/50	47/49.83	46/49.8	36/45.8
POLY-3 PERCENT (g)	94%	94.3%	92.4%	78.6%
TERMINAL (d)	34/37 (92%)	31/33 (94%)	29/32 (91%)	28/36 (78%)
FIRST INCIDENCE	328	424	537	360
HC TUMORS SAME RTE	259/300 (86%)			
HC TUMORS ALL RTES	976/1149 (85%)			

STATISTICAL TESTS

POLY 3	P=0.005N**	P=0.640	P=0.529N	P=0.024N*
POLY 1.5	P=0.003N**	P=0.650	P=0.515N	P=0.015N*
POLY 6	P=0.008N**	P=0.620	P=0.554N	P=0.035N*
COCH-ARM / FISHERS	P<0.001N**	P=0.661N	P=0.500N	P=0.003N**
MAX-ISO-POLY-3	P=0.007N**	P=0.471	P=0.372N	P=0.014N*
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Adrenal Cortex
Adenoma**

TUMOR RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.58	0/46.91	0/44.98	0/47.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	2/299 (1%)			
HC TUMORS ALL RTES	5/1244 (0%)			

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Adrenal Medulla
Pheochromocytoma Benign**

TUMOR RATES

OVERALL (a)	3/50 (6%)	0/50 (0%)	2/49 (4%)	0/50 (0%)
POLY-3 RATE (b)	3/44.67	0/46.91	2/44.4	0/47.17
POLY-3 PERCENT (g)	6.7%	0%	4.5%	0%
TERMINAL (d)	2/36 (6%)	0/40 (0%)	1/37 (3%)	0/41 (0%)
FIRST INCIDENCE	708	---	631	---
HC TUMORS SAME RTE	6/296 (2%)			
HC TUMORS ALL RTES	14/1239 (1%)			

STATISTICAL TESTS

POLY 3	P=0.123N	P=0.110N	P=0.503N	P=0.109N
POLY 1.5	P=0.124N	P=0.114N	P=0.507N	P=0.114N
POLY 6	P=0.122N	P=0.105N	P=0.495N	P=0.104N
COCH-ARM / FISHERS	P=0.126N	P=0.121N	P=0.510N	P=0.121N
MAX-ISO-POLY-3	P=0.041N*	P=0.038N*	P=0.326N	P=0.038N*
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Adrenal Medulla
Pheochromocytoma: Benign, Complex, Malignant, NOS**

TUMOR RATES

OVERALL (a)	4/50 (8%)	0/50 (0%)	2/49 (4%)	0/50 (0%)
POLY-3 RATE (b)	4/44.67	0/46.91	2/44.4	0/47.17
POLY-3 PERCENT (g)	9%	0%	4.5%	0%
TERMINAL (d)	3/36 (8%)	0/40 (0%)	1/37 (3%)	0/41 (0%)
FIRST INCIDENCE	708	---	631	---
HC TUMORS SAME RTE	7/296 (2%)			
HC TUMORS ALL RTES	22/1239 (2%)			

STATISTICAL TESTS

POLY 3	P=0.060N	P=0.054N	P=0.340N	P=0.054N
POLY 1.5	P=0.060N	P=0.057N	P=0.344N	P=0.057N
POLY 6	P=0.059N	P=0.051N	P=0.332N	P=0.050N*
COCH-ARM / FISHERS	P=0.062N	P=0.059N	P=0.349N	P=0.059N
MAX-ISO-POLY-3	P=0.013N*	P=0.019N*	P=0.203N	P=0.019N*
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM
Harderian Gland Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	3/50 (6%)	2/50 (4%)	4/50 (8%)	2/50 (4%)
POLY-3 RATE (b)	3/44.58	2/46.91	4/44.98	2/47.43
POLY-3 PERCENT (g)	6.7%	4.3%	8.9%	4.2%
TERMINAL (d)	3/36 (8%)	2/40 (5%)	4/37 (11%)	1/41 (2%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	663
HC TUMORS SAME RTE	29/300 (10%)			
HC TUMORS ALL RTEs	128/1249 (10%)			

STATISTICAL TESTS

POLY 3	P=0.456N	P=0.477N	P=0.505	P=0.472N
POLY 1.5	P=0.467N	P=0.487N	P=0.501	P=0.485N
POLY 6	P=0.440N	P=0.463N	P=0.512	P=0.454N
COCH-ARM / FISHERS	P=0.479N	P=0.500N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.498N	P=0.308N	P=0.352	P=0.304N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTEs	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM
Harderian Gland Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/44.58	1/46.91	0/44.98	1/47.17
POLY-3 PERCENT (g)	4.5%	2.1%	0%	2.1%
TERMINAL (d)	2/36 (6%)	1/40 (3%)	0/37 (0%)	1/41 (2%)
FIRST INCIDENCE	731 (T)	731 (T)	---	731 (T)
HC TUMORS SAME RTE	10/300 (3%)			
HC TUMORS ALL RTES	33/1249 (3%)			

STATISTICAL TESTS

POLY 3	P=0.367N	P=0.482N	P=0.235N	P=0.480N
POLY 1.5	P=0.367N	P=0.490N	P=0.237N	P=0.489N
POLY 6	P=0.367N	P=0.472N	P=0.232N	P=0.468N
COCH-ARM / FISHERS	P=0.366N	P=0.500N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.225N	P=0.271N	P=0.076N	P=0.270N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM
Harderian Gland Carcinoma or Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	5/50 (10%)	2/50 (4%)	4/50 (8%)	3/50 (6%)
POLY-3 RATE (b)	5/44.58	2/46.91	4/44.98	3/47.43
POLY-3 PERCENT (g)	11.2%	4.3%	8.9%	6.3%
TERMINAL (d)	5/36 (14%)	2/40 (5%)	4/37 (11%)	2/41 (5%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	663
HC TUMORS SAME RTE	38/300 (13%)			
HC TUMORS ALL RTES	160/1249 (13%)			

STATISTICAL TESTS

POLY 3	P=0.372N	P=0.196N	P=0.494N	P=0.323N
POLY 1.5	P=0.380N	P=0.205N	P=0.499N	P=0.338N
POLY 6	P=0.360N	P=0.184N	P=0.486N	P=0.302N
COCH-ARM / FISHERS	P=0.389N	P=0.218N	P=0.500N	P=0.357N
MAX-ISO-POLY-3	P=0.318N	P=0.111N	P=0.358N	P=0.211N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Intestine Small: Jejunum
Carcinoma**

TUMOR RATES

	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.58	0/46.91	0/44.98	0/47.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	4/1249 (0%)			

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Intestine Small: Site Unspecified
Carcinoma**

TUMOR RATES

	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.58	0/46.91	0/44.98	0/47.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	6/1249 (1%)			

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Hepatocellular Adenoma**

TUMOR RATES

OVERALL (a)	19/50 (38%)	13/50 (26%)	15/50 (30%)	12/50 (24%)
POLY-3 RATE (b)	19/46.58	13/47.11	15/46.39	12/47.28
POLY-3 PERCENT (g)	40.8%	27.6%	32.3%	25.4%
TERMINAL (d)	14/36 (39%)	12/40 (30%)	11/37 (30%)	11/41 (27%)
FIRST INCIDENCE	481	678	589	703
HC TUMORS SAME RTE	82/299 (27%)			
HC TUMORS ALL RTES	345/1245 (28%)			

STATISTICAL TESTS

POLY 3	P=0.108N	P=0.127N	P=0.263N	P=0.083N
POLY 1.5	P=0.114N	P=0.134N	P=0.268N	P=0.089N
POLY 6	P=0.100N	P=0.119N	P=0.251N	P=0.075N
COCH-ARM / FISHERS	P=0.119N	P=0.142N	P=0.263N	P=0.097N
MAX-ISO-POLY-3	P=0.084N	P=0.089N	P=0.198N	P=0.055N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Hepatocellular Carcinoma**

TUMOR RATES

OVERALL (a)	5/50 (10%)	4/50 (8%)	7/50 (14%)	0/50 (0%)
POLY-3 RATE (b)	5/44.99	4/47.11	7/45.55	0/47.17
POLY-3 PERCENT (g)	11.1%	8.5%	15.4%	0%
TERMINAL (d)	3/36 (8%)	3/40 (8%)	5/37 (14%)	0/41 (0%)
FIRST INCIDENCE	669	678	589	---
HC TUMORS SAME RTE	34/299 (11%)			
HC TUMORS ALL RTES	131/1245 (11%)			

STATISTICAL TESTS

POLY 3	P=0.047N*	P=0.471N	P=0.388	P=0.027N*
POLY 1.5	P=0.050N*	P=0.483N	P=0.382	P=0.028N*
POLY 6	P=0.042N*	P=0.456N	P=0.396	P=0.025N*
COCH-ARM / FISHERS	P=0.056N	P=0.500N	P=0.380	P=0.028N*
MAX-ISO-POLY-3	P=0.038N*	P=0.340N	P=0.278	P=0.010N**
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Hepatocellular Carcinoma or Hepatoblastoma**

TUMOR RATES

OVERALL (a)	5/50 (10%)	4/50 (8%)	7/50 (14%)	0/50 (0%)
POLY-3 RATE (b)	5/44.99	4/47.11	7/45.55	0/47.17
POLY-3 PERCENT (g)	11.1%	8.5%	15.4%	0%
TERMINAL (d)	3/36 (8%)	3/40 (8%)	5/37 (14%)	0/41 (0%)
FIRST INCIDENCE	669	678	589	---
HC TUMORS SAME RTE	34/299 (11%)			
HC TUMORS ALL RTES	136/1245 (11%)			

STATISTICAL TESTS

POLY 3	P=0.047N*	P=0.471N	P=0.388	P=0.027N*
POLY 1.5	P=0.050N*	P=0.483N	P=0.382	P=0.028N*
POLY 6	P=0.042N*	P=0.456N	P=0.396	P=0.025N*
COCH-ARM / FISHERS	P=0.056N	P=0.500N	P=0.380	P=0.028N*
MAX-ISO-POLY-3	P=0.038N*	P=0.340N	P=0.278	P=0.010N**
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Hepatocellular Carcinoma or Hepatocellular Adenoma**

TUMOR RATES

OVERALL (a)	24/50 (48%)	15/50 (30%)	20/50 (40%)	12/50 (24%)
POLY-3 RATE (b)	24/46.99	15/47.11	20/46.48	12/47.28
POLY-3 PERCENT (g)	51.1%	31.8%	43%	25.4%
TERMINAL (d)	17/36 (47%)	14/40 (35%)	15/37 (41%)	11/41 (27%)
FIRST INCIDENCE	481	678	589	703
HC TUMORS SAME RTE	104/299 (35%)			
HC TUMORS ALL RTES	419/1245 (34%)			

STATISTICAL TESTS

POLY 3	P=0.017N*	P=0.043N*	P=0.282N	P=0.007N**
POLY 1.5	P=0.019N*	P=0.045N*	P=0.283N	P=0.008N**
POLY 6	P=0.015N*	P=0.041N*	P=0.275N	P=0.006N**
COCH-ARM / FISHERS	P=0.022N*	P=0.050N*	P=0.273N	P=0.011N*
MAX-ISO-POLY-3	P=0.007N**	P=0.027N*	P=0.218N	P=0.004N**
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma**

TUMOR RATES

OVERALL (a)	24/50 (48%)	15/50 (30%)	20/50 (40%)	12/50 (24%)
POLY-3 RATE (b)	24/46.99	15/47.11	20/46.48	12/47.28
POLY-3 PERCENT (g)	51.1%	31.8%	43%	25.4%
TERMINAL (d)	17/36 (47%)	14/40 (35%)	15/37 (41%)	11/41 (27%)
FIRST INCIDENCE	481	678	589	703
HC TUMORS SAME RTE	104/299 (35%)			
HC TUMORS ALL RTES	421/1245 (34%)			

STATISTICAL TESTS

POLY 3	P=0.017N*	P=0.043N*	P=0.282N	P=0.007N**
POLY 1.5	P=0.019N*	P=0.045N*	P=0.283N	P=0.008N**
POLY 6	P=0.015N*	P=0.041N*	P=0.275N	P=0.006N**
COCH-ARM / FISHERS	P=0.022N*	P=0.050N*	P=0.273N	P=0.011N*
MAX-ISO-POLY-3	P=0.007N**	P=0.027N*	P=0.218N	P=0.004N**
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Hepatocolangiocarcinoma**

TUMOR RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/44.58	0/46.91	0/44.98	1/47.28
POLY-3 PERCENT (g)	0%	0%	0%	2.1%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	---	---	703
HC TUMORS SAME RTE	2/299 (1%)			
HC TUMORS ALL RTES	2/1245 (0%)			

STATISTICAL TESTS

POLY 3	P=0.204	(e)	(e)	P=0.512
POLY 1.5	P=0.202	(e)	(e)	P=0.506
POLY 6	P=0.208	(e)	(e)	P=0.519
COCH-ARM / FISHERS	P=0.198	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.144	(e)	(e)	P=0.173
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM
Lung				
Alveolar/Bronchiolar Adenoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	6/50 (12%)	4/50 (8%)	10/50 (20%)
POLY-3 RATE (b)	1/44.58	6/46.91	4/44.98	10/48.01
POLY-3 PERCENT (g)	2.2%	12.8%	8.9%	20.8%
TERMINAL (d)	1/36 (3%)	6/40 (15%)	4/37 (11%)	7/41 (17%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	649
HC TUMORS SAME RTE	15/300 (5%)			
HC TUMORS ALL RTES	65/1248 (5%)			

STATISTICAL TESTS

POLY 3	P=0.007**	P=0.064	P=0.181	P=0.006**
POLY 1.5	P=0.006**	P=0.061	P=0.179	P=0.005**
POLY 6	P=0.009**	P=0.070	P=0.185	P=0.008**
COCH-ARM / FISHERS	P=0.006**	P=0.056	P=0.181	P=0.004**
MAX-ISO-POLY-3	P=0.005**	P=0.031*	P=0.086	P=0.003**
HISTCONT SAME RTE	P=0.005**	P=0.033*	P=0.104	P=0.003**
HISTCONT ALL RTES	P<0.001**	P=0.032*	P=0.098	P=0.003**

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung
Alveolar/Bronchiolar Carcinoma**

TUMOR RATES

OVERALL (a)	0/50 (0%)	7/50 (14%)	5/50 (10%)	4/50 (8%)
POLY-3 RATE (b)	0/44.58	7/46.99	5/44.98	4/47.17
POLY-3 PERCENT (g)	0%	14.9%	11.1%	8.5%
TERMINAL (d)	0/36 (0%)	6/40 (15%)	5/37 (14%)	4/41 (10%)
FIRST INCIDENCE	---	709	731 (T)	731 (T)
HC TUMORS SAME RTE	8/300 (3%)			
HC TUMORS ALL RTES	47/1248 (4%)			

STATISTICAL TESTS

POLY 3	P=0.277	P=0.009**	P=0.031*	P=0.068
POLY 1.5	P=0.259	P=0.009**	P=0.031*	P=0.065
POLY 6	P=0.303	P=0.010**	P=0.032*	P=0.073
COCH-ARM / FISHERS	P=0.240	P=0.006**	P=0.028*	P=0.059
MAX-ISO-POLY-3	P=0.043*	P=0.003**	P=0.010**	P=0.025*
HISTCONT SAME RTE	P=0.050*	P=0.004**	P=0.011*	P=0.027*
HISTCONT ALL RTES	P=0.048*	P=0.004**	P=0.010**	P=0.026*

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma**

TUMOR RATES

OVERALL (a)	1/50 (2%)	9/50 (18%)	8/50 (16%)	14/50 (28%)
POLY-3 RATE (b)	1/44.58	9/46.99	8/44.98	14/48.01
POLY-3 PERCENT (g)	2.2%	19.2%	17.8%	29.2%
TERMINAL (d)	1/36 (3%)	8/40 (20%)	8/37 (22%)	11/41 (27%)
FIRST INCIDENCE	731 (T)	709	731 (T)	649
HC TUMORS SAME RTE	23/300 (8%)			
HC TUMORS ALL RTES	107/1248 (9%)			

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.010**	P=0.016*	P<0.001**
POLY 1.5	P<0.001**	P=0.009**	P=0.016*	P<0.001**
POLY 6	P=0.002**	P=0.012*	P=0.016*	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.008**	P=0.015*	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.005**	P=0.006**	P<0.001**
HISTCONT SAME RTE	P<0.001**	P=0.005**	P=0.006**	P<0.001**
HISTCONT ALL RTES	P<0.001**	P=0.005**	P=0.006**	P<0.001**

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM
Mammary Gland Adenosquamous Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/44.58	0/46.91	1/44.98	2/47.45
POLY-3 PERCENT (g)	0%	0%	2.2%	4.2%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	1/37 (3%)	1/41 (2%)
FIRST INCIDENCE	---	---	731 (T)	655
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	0/1249 (0%)			

STATISTICAL TESTS

POLY 3	P=0.075	(e)	P=0.502	P=0.251
POLY 1.5	P=0.073	(e)	P=0.500	P=0.245
POLY 6	P=0.078	(e)	P=0.504	P=0.261
COCH-ARM / FISHERS	P=0.070	(e)	P=0.500	P=0.247
MAX-ISO-POLY-3	P=0.095	(e)	P=0.161	P=0.090
HISTCONT SAME RTE	P=0.009**	(e)	P=0.024*	P=0.020*
HISTCONT ALL RTES	P<0.001**	(e)	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM
Mammary Gland Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/44.58	0/46.91	0/44.98	1/47.47
POLY-3 PERCENT (g)	4.5%	0%	0%	2.1%
TERMINAL (d)	2/36 (6%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	731 (T)	---	---	649
HC TUMORS SAME RTE	3/300 (1%)			
HC TUMORS ALL RTES	16/1249 (1%)			

STATISTICAL TESTS

POLY 3	P=0.470N	P=0.226N	P=0.235N	P=0.478N
POLY 1.5	P=0.467N	P=0.231N	P=0.237N	P=0.488N
POLY 6	P=0.476N	P=0.220N	P=0.232N	P=0.464N
COCH-ARM / FISHERS	P=0.461N	P=0.247N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.131N	P=0.076N	P=0.076N	P=0.269N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM
Ovary				
Cystadenoma				
TUMOR RATES				
OVERALL (a)	3/50 (6%)	1/50 (2%)	1/50 (2%)	2/49 (4%)
POLY-3 RATE (b)	3/44.58	1/46.91	1/44.98	2/46.18
POLY-3 PERCENT (g)	6.7%	2.1%	2.2%	4.3%
TERMINAL (d)	3/36 (8%)	1/40 (3%)	1/37 (3%)	1/40 (3%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	730
HC TUMORS SAME RTE	17/291 (6%)			
HC TUMORS ALL RTES	46/1221 (4%)			

STATISTICAL TESTS

POLY 3	P=0.480N	P=0.287N	P=0.302N	P=0.484N
POLY 1.5	P=0.481N	P=0.295N	P=0.305N	P=0.495N
POLY 6	P=0.477N	P=0.277N	P=0.297N	P=0.468N
COCH-ARM / FISHERS	P=0.482N	P=0.309N	P=0.309N	P=0.510N
MAX-ISO-POLY-3	P=0.287N	P=0.147N	P=0.153N	P=0.314N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Pituitary Gland: Pars Distalis or Unspecified Site
Adenoma**

TUMOR RATES

OVERALL (a)	5/46 (11%)	7/49 (14%)	5/47 (11%)	9/48 (19%)
POLY-3 RATE (b)	5/40.98	7/45.94	5/42.46	9/47.07
POLY-3 PERCENT (g)	12.2%	15.2%	11.8%	19.1%
TERMINAL (d)	5/34 (15%)	6/39 (15%)	5/35 (14%)	6/41 (15%)
FIRST INCIDENCE	731 (T)	723	731 (T)	470
HC TUMORS SAME RTE	41/294 (14%)			
HC TUMORS ALL RTES	97/1216 (8%)			

STATISTICAL TESTS

POLY 3	P=0.237	P=0.461	P=0.608N	P=0.278
POLY 1.5	P=0.216	P=0.446	P=0.614N	P=0.251
POLY 6	P=0.267	P=0.481	P=0.600N	P=0.315
COCH-ARM / FISHERS	P=0.189	P=0.425	P=0.616N	P=0.218
MAX-ISO-POLY-3	P=0.313	P=0.347	P=0.475N	P=0.203
HISTCONT SAME RTE	P=0.379	P=0.452	P=1.000	P=0.258
HISTCONT ALL RTES	P=0.046*	P=0.247	P=0.448	P=0.106

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Pituitary Gland: Pars Distalis or Unspecified Site
Carcinoma or Adenoma**

TUMOR RATES

OVERALL (a)	6/46 (13%)	7/49 (14%)	5/47 (11%)	9/48 (19%)
POLY-3 RATE (b)	6/41.07	7/45.94	5/42.46	9/47.07
POLY-3 PERCENT (g)	14.6%	15.2%	11.8%	19.1%
TERMINAL (d)	5/34 (15%)	6/39 (15%)	5/35 (14%)	6/41 (15%)
FIRST INCIDENCE	708	723	731 (T)	470
HC TUMORS SAME RTE	42/294 (14%)			
HC TUMORS ALL RTES	99/1216 (8%)			

STATISTICAL TESTS

POLY 3	P=0.322	P=0.586	P=0.477N	P=0.391
POLY 1.5	P=0.299	P=0.570	P=0.482N	P=0.360
POLY 6	P=0.355	P=0.605	P=0.468N	P=0.433
COCH-ARM / FISHERS	P=0.268	P=0.549	P=0.485N	P=0.319
MAX-ISO-POLY-3	P=0.420	P=0.468	P=0.352N	P=0.299
HISTCONT SAME RTE	P=0.498	P=0.601	P=1.000	P=0.387
HISTCONT ALL RTES	P=0.054	P=0.260	P=0.462	P=0.114

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Pituitary Gland: Pars Intermedia
Adenoma**

TUMOR RATES

OVERALL (a)	0/46 (0%)	0/49 (0%)	4/47 (9%)	0/48 (0%)
POLY-3 RATE (b)	0/40.98	0/45.91	4/42.46	0/45.98
POLY-3 PERCENT (g)	0%	0%	9.4%	0%
TERMINAL (d)	0/34 (0%)	0/39 (0%)	4/35 (11%)	0/41 (0%)
FIRST INCIDENCE	---	---	731 (T)	---
HC TUMORS SAME RTE	3/294 (1%)			
HC TUMORS ALL RTES	12/1216 (1%)			

STATISTICAL TESTS

POLY 3	P=0.551	(e)	P=0.064	(e)
POLY 1.5	P=0.532	(e)	P=0.063	(e)
POLY 6	P=0.576	(e)	P=0.066	(e)
COCH-ARM / FISHERS	P=0.507	(e)	P=0.061	(e)
MAX-ISO-POLY-3	P=0.132	(e)	P=0.022*	(e)
HISTCONT SAME RTE	P=0.157	(e)	P=0.024*	(e)
HISTCONT ALL RTES	P=0.151	(e)	P=0.004**	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Skin
Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	8/50 (16%)	4/50 (8%)	4/50 (8%)	1/50 (2%)
POLY-3 RATE (b)	8/46.71	4/48	4/46	1/47.17
POLY-3 PERCENT (g)	17.1%	8.3%	8.7%	2.1%
TERMINAL (d)	2/36 (6%)	1/40 (3%)	2/37 (5%)	1/41 (2%)
FIRST INCIDENCE	562	505	537	731 (T)
HC TUMORS SAME RTE	14/300 (5%)			
HC TUMORS ALL RTES	53/1249 (4%)			

STATISTICAL TESTS

POLY 3	P=0.014N*	P=0.164N	P=0.184N	P=0.015N*
POLY 1.5	P=0.014N*	P=0.169N	P=0.182N	P=0.015N*
POLY 6	P=0.014N*	P=0.159N	P=0.187N	P=0.015N*
COCH-ARM / FISHERS	P=0.014N*	P=0.178N	P=0.178N	P=0.015N*
MAX-ISO-POLY-3	P=0.008N**	P=0.102N	P=0.115N	P=0.006N**
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Skin
Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	8/50 (16%)	4/50 (8%)	4/50 (8%)	1/50 (2%)
POLY-3 RATE (b)	8/46.71	4/48	4/46	1/47.17
POLY-3 PERCENT (g)	17.1%	8.3%	8.7%	2.1%
TERMINAL (d)	2/36 (6%)	1/40 (3%)	2/37 (5%)	1/41 (2%)
FIRST INCIDENCE	562	505	537	731 (T)
HC TUMORS SAME RTE	14/300 (5%)			
HC TUMORS ALL RTES	53/1249 (4%)			

STATISTICAL TESTS

POLY 3	P=0.014N*	P=0.164N	P=0.184N	P=0.015N*
POLY 1.5	P=0.014N*	P=0.169N	P=0.182N	P=0.015N*
POLY 6	P=0.014N*	P=0.159N	P=0.187N	P=0.015N*
COCH-ARM / FISHERS	P=0.014N*	P=0.178N	P=0.178N	P=0.015N*
MAX-ISO-POLY-3	P=0.008N**	P=0.102N	P=0.115N	P=0.006N**
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM
Skin				
Fibrous Histiocytoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/44.58	2/47.11	0/44.98	0/47.17
POLY-3 PERCENT (g)	2.2%	4.3%	0%	0%
TERMINAL (d)	1/36 (3%)	1/40 (3%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	731 (T)	678	---	---
HC TUMORS SAME RTE	2/300 (1%)			
HC TUMORS ALL RTES	7/1249 (1%)			

STATISTICAL TESTS

POLY 3	P=0.181N	P=0.519	P=0.498N	P=0.489N
POLY 1.5	P=0.184N	P=0.511	P=0.500N	P=0.494N
POLY 6	P=0.175N	P=0.531	P=0.496N	P=0.482N
COCH-ARM / FISHERS	P=0.188N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.183N	P=0.302	P=0.158N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM
Skin				
Sarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	7/50 (14%)	2/50 (4%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	7/46.71	2/47.8	3/45.4	1/47.17
POLY-3 PERCENT (g)	15%	4.2%	6.6%	2.1%
TERMINAL (d)	1/36 (3%)	0/40 (0%)	2/37 (5%)	1/41 (2%)
FIRST INCIDENCE	562	505	610	731 (T)
HC TUMORS SAME RTE	12/300 (4%)			
HC TUMORS ALL RTES	27/1249 (2%)			

STATISTICAL TESTS

POLY 3	P=0.029N*	P=0.074N	P=0.169N	P=0.029N*
POLY 1.5	P=0.029N*	P=0.076N	P=0.165N	P=0.030N*
POLY 6	P=0.029N*	P=0.072N	P=0.174N	P=0.028N*
COCH-ARM / FISHERS	P=0.029N*	P=0.080N	P=0.159N	P=0.030N*
MAX-ISO-POLY-3	P=0.010N**	P=0.037N*	P=0.101N	P=0.012N*
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Spleen
Hemangiosarcoma**

TUMOR RATES

OVERALL (a)	1/50 (2%)	1/49 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/44.58	1/46.13	1/45.42	0/47.17
POLY-3 PERCENT (g)	2.2%	2.2%	2.2%	0%
TERMINAL (d)	1/36 (3%)	1/40 (3%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	731 (T)	731 (T)	603	---
HC TUMORS SAME RTE	3/297 (1%)			
HC TUMORS ALL RTES	24/1230 (2%)			

STATISTICAL TESTS

POLY 3	P=0.302N	P=0.753N	P=0.756N	P=0.489N
POLY 1.5	P=0.306N	P=0.758N	P=0.759N	P=0.494N
POLY 6	P=0.296N	P=0.746N	P=0.752N	P=0.482N
COCH-ARM / FISHERS	P=0.310N	P=0.747	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.336N	P=0.490N	P=0.494N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Stomach, Forestomach
Squamous Cell Papilloma**

TUMOR RATES

	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/44.58	0/46.91	0/44.98	2/47.17
POLY-3 PERCENT (g)	0%	0%	0%	4.2%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	2/41 (5%)
FIRST INCIDENCE	---	---	---	731 (T)
HC TUMORS SAME RTE	3/300 (1%)			
HC TUMORS ALL RTES	20/1249 (2%)			

STATISTICAL TESTS

POLY 3	P=0.047*	(e)	(e)	P=0.250
POLY 1.5	P=0.046*	(e)	(e)	P=0.244
POLY 6	P=0.048*	(e)	(e)	P=0.258
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.043*	(e)	(e)	P=0.088
HISTCONT SAME RTE	P=0.050*	(e)	(e)	P=0.091
HISTCONT ALL RTES	P=0.048*	(e)	(e)	P=0.101

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM
Uterus				
Polyp Stromal				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	2/50 (4%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	0/44.58	2/47.49	2/45.46	3/47.22
POLY-3 PERCENT (g)	0%	4.2%	4.4%	6.4%
TERMINAL (d)	0/36 (0%)	1/40 (3%)	1/37 (3%)	2/41 (5%)
FIRST INCIDENCE	---	547	589	719
HC TUMORS SAME RTE	14/300 (5%)			
HC TUMORS ALL RTES	33/1249 (3%)			

STATISTICAL TESTS

POLY 3	P=0.121	P=0.252	P=0.241	P=0.129
POLY 1.5	P=0.115	P=0.245	P=0.239	P=0.125
POLY 6	P=0.129	P=0.260	P=0.246	P=0.137
COCH-ARM / FISHERS	P=0.108	P=0.247	P=0.247	P=0.121
MAX-ISO-POLY-3	P=0.097	P=0.090	P=0.080	P=0.047*
HISTCONT SAME RTE	P=0.114	P=0.108	P=0.096	P=0.054
HISTCONT ALL RTES	P=0.109	P=0.102	P=0.091	P=0.051

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM
All Organs				
Hemangiosarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	4/50 (8%)	2/50 (4%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	4/44.58	2/47.08	2/45.42	1/47.17
POLY-3 PERCENT (g)	9%	4.3%	4.4%	2.1%
TERMINAL (d)	4/36 (11%)	1/40 (3%)	1/37 (3%)	1/41 (2%)
FIRST INCIDENCE	731 (T)	687	603	731 (T)
HC TUMORS SAME RTE	12/300 (4%)			
HC TUMORS ALL RTES	60/1249 (5%)			

STATISTICAL TESTS

POLY 3	P=0.131N	P=0.312N	P=0.328N	P=0.162N
POLY 1.5	P=0.134N	P=0.323N	P=0.334N	P=0.170N
POLY 6	P=0.127N	P=0.298N	P=0.319N	P=0.152N
COCH-ARM / FISHERS	P=0.137N	P=0.339N	P=0.339N	P=0.181N
MAX-ISO-POLY-3	P=0.110N	P=0.188N	P=0.196N	P=0.080N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**All Organs
Hemangiosarcoma or Hemangioma**

TUMOR RATES

	#	#	#	#
OVERALL (a)	4/50 (8%)	3/50 (6%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	4/44.58	3/47.08	2/45.42	1/47.17
POLY-3 PERCENT (g)	9%	6.4%	4.4%	2.1%
TERMINAL (d)	4/36 (11%)	2/40 (5%)	1/37 (3%)	1/41 (2%)
FIRST INCIDENCE	731 (T)	687	603	731 (T)
HC TUMORS SAME RTE	15/300 (5%)			
HC TUMORS ALL RTES	79/1249 (6%)			

STATISTICAL TESTS

POLY 3	P=0.107N	P=0.470N	P=0.328N	P=0.162N
POLY 1.5	P=0.110N	P=0.483N	P=0.334N	P=0.170N
POLY 6	P=0.102N	P=0.452N	P=0.319N	P=0.152N
COCH-ARM / FISHERS	P=0.114N	P=0.500N	P=0.339N	P=0.181N
MAX-ISO-POLY-3	P=0.127N	P=0.325N	P=0.196N	P=0.080N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM
All Organs				
Histiocytic Sarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	1/45.17	0/46.91	2/45.18	2/47.7
POLY-3 PERCENT (g)	2.2%	0%	4.4%	4.2%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	1/41 (2%)
FIRST INCIDENCE	540	---	696	568
HC TUMORS SAME RTE	8/300 (3%)			
HC TUMORS ALL RTES	31/1249 (3%)			

STATISTICAL TESTS

POLY 3	P=0.258	P=0.492N	P=0.500	P=0.519
POLY 1.5	P=0.253	P=0.496N	P=0.499	P=0.510
POLY 6	P=0.267	P=0.488N	P=0.504	P=0.531
COCH-ARM / FISHERS	P=0.245	P=0.500N	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.285	P=0.158N	P=0.281	P=0.302
HISTCONT SAME RTE	P=0.343	(e)	P=0.363	P=0.390
HISTCONT ALL RTES	P=0.329	(e)	P=0.350	P=0.377

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

All Organs
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type

TUMOR RATES	#	#	#	#
OVERALL (a)	17/50 (34%)	9/50 (18%)	15/50 (30%)	11/50 (22%)
POLY-3 RATE (b)	17/45.76	9/47.4	15/45.5	11/47.53
POLY-3 PERCENT (g)	37.2%	19%	33%	23.2%
TERMINAL (d)	13/36 (36%)	8/40 (20%)	13/37 (35%)	8/41 (20%)
FIRST INCIDENCE	591	583	631	649
HC TUMORS SAME RTE	64/300 (21%)			
HC TUMORS ALL RTES	284/1249 (23%)			

STATISTICAL TESTS

POLY 3	P=0.198N	P=0.040N*	P=0.421N	P=0.104N
POLY 1.5	P=0.209N	P=0.045N*	P=0.422N	P=0.116N
POLY 6	P=0.183N	P=0.035N*	P=0.417N	P=0.090N
COCH-ARM / FISHERS	P=0.223N	P=0.055N	P=0.415N	P=0.133N
MAX-ISO-POLY-3	P=0.105N	P=0.025N*	P=0.337N	P=0.072N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**All Organs
Benign Tumors**

TUMOR RATES

	#	#	#	#
OVERALL (a)	22/50 (44%)	24/50 (48%)	30/50 (60%)	28/50 (56%)
POLY-3 RATE (b)	22/46.58	24/47.72	30/46.87	28/48.9
POLY-3 PERCENT (g)	47.2%	50.3%	64%	57.3%
TERMINAL (d)	17/36 (47%)	21/40 (53%)	25/37 (68%)	21/41 (51%)
FIRST INCIDENCE	481	547	589	470
HC TUMORS SAME RTE	170/300 (57%)			
HC TUMORS ALL RTES	644/1249 (52%)			

STATISTICAL TESTS

POLY 3	P=0.150	P=0.463	P=0.072	P=0.217
POLY 1.5	P=0.128	P=0.444	P=0.072	P=0.189
POLY 6	P=0.191	P=0.490	P=0.078	P=0.265
COCH-ARM / FISHERS	P=0.107	P=0.421	P=0.080	P=0.159
MAX-ISO-POLY-3	P=0.154	P=0.382	P=0.047*	P=0.168
HISTCONT SAME RTE	P=0.184	P=0.498	P=0.054	P=0.210
HISTCONT ALL RTES	P=0.175	P=0.485	P=0.051	P=0.197

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM
All Organs				
Malignant Tumors				
TUMOR RATES	#	#	#	#
OVERALL (a)	33/50 (66%)	28/50 (56%)	33/50 (66%)	22/50 (44%)
POLY-3 RATE (b)	33/48.27	28/49.16	33/48.63	22/48.7
POLY-3 PERCENT (g)	68.4%	57%	67.9%	45.2%
TERMINAL (d)	22/36 (61%)	20/40 (50%)	23/37 (62%)	15/41 (37%)
FIRST INCIDENCE	540	505	345	568
HC TUMORS SAME RTE	149/300 (50%)			
HC TUMORS ALL RTES	629/1249 (50%)			

STATISTICAL TESTS

POLY 3	P=0.021N*	P=0.168N	P=0.566N	P=0.016N*
POLY 1.5	P=0.023N*	P=0.182N	P=0.571N	P=0.017N*
POLY 6	P=0.019N*	P=0.158N	P=0.565N	P=0.014N*
COCH-ARM / FISHERS	P=0.026N*	P=0.206N	P=0.583N	P=0.022N*
MAX-ISO-POLY-3	P=0.014N*	P=0.123N	P=0.477N	P=0.009N**
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**All Organs
Malignant and Benign Tumors**

TUMOR RATES

	#	#	#	#
OVERALL (a)	42/50 (84%)	37/50 (74%)	44/50 (88%)	34/50 (68%)
POLY-3 RATE (b)	42/49.41	37/49.74	44/49.11	34/49.44
POLY-3 PERCENT (g)	85%	74.4%	89.6%	68.8%
TERMINAL (d)	29/36 (81%)	28/40 (70%)	33/37 (89%)	26/41 (63%)
FIRST INCIDENCE	481	505	345	470
HC TUMORS SAME RTE	240/300 (80%)			
HC TUMORS ALL RTES	939/1249 (75%)			

STATISTICAL TESTS

POLY 3	P=0.064N	P=0.142N	P=0.349	P=0.044N*
POLY 1.5	P=0.065N	P=0.149N	P=0.365	P=0.046N*
POLY 6	P=0.063N	P=0.138N	P=0.328	P=0.043N*
COCH-ARM / FISHERS	P=0.069N	P=0.163N	P=0.387	P=0.050N*
MAX-ISO-POLY-3	P=0.031N*	P=0.094N	P=0.244	P=0.026N*
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

LEGEND

- (a) Number of tumor-bearing animals/number of animals examined at site.
 - (b) Number of tumor-bearing animals/Poly-3 number
 - (d) Observed incidence at terminal kill.
 - (e) Value of Statistic cannot be computed.
 - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
 - (g) Poly-3 adjusted lifetime tumor incidence.
 - (h) Value of Historical Controls statistic is only calculated when Poly-3 trend is positive and when there is more than one tumor in the treatment groups.
 - (I) Interim sacrifice
 - (T) Terminal sacrifice
 - # Tumor rates based on numbers of animals necropsied.
 - * To the right of any statistical result, indicates significance at ($P \leq 0.05$).
 - ** To the right of any statistical result, indicates significance at ($P \leq 0.01$).
 - N Indicates a negative trend for all tests
- The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***